11/19/2008
An Impending Crisis In The Provision Of Histopathology Expertise For Mouse Functional Genomics - Journal Of Pathology (Medical News Today)
Research paper publishing today in the Journal of Pathology. The generation of new mouse models of human disease is accelerating rapidly due to the completion of whole-genome sequencing efforts and technological advances in the manipulation of the mouse genome. The speed of progress in this endeavour has highlighted the shortage of experts to fully characterise the new mouse lines produced.
MORE INFO
|
11/22/2008
Dr. Duane A. Kimmey: Lump's diagnois can be costly (Detroit News)
Dear Dr. Kimmey: I have a 9-year-old male Alaskan malamute. He was neutered when he was 3. We noticed a bump about the size of a small grape on his anal area about two weeks ago.
MORE INFO
|
11/18/2008
Impending crisis in provision of histopathology expertise for mouse functional genomics (News-Medical-Net)
The generation of new mouse models of human disease is accelerating rapidly due to the completion of whole-genome sequencing efforts and technological advances in the manipulation of the mouse genome.
MORE INFO
|
11/21/2008
Aeolus Pharmaceuticals Initiates Pivotal Animal Study of AEOL 10150 as a Countermeasure to Radiation Exposure (Business Wire via Yahoo! Finance)
LAGUNA NIGUEL, Calif.----Aeolus Pharmaceuticals, Inc. announced today that it has initiated the first of two expected pivotal studies of AEOL 10150 as a countermeasure to nuclear and radiological exposure.
MORE INFO
|
11/13/2008
Arthritis - MorphoSys Publishes Preclinical Data From MOR103 Program (Medical News Today)
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
MORE INFO
|
11/13/2008
DJ HUGIN NEWS/MorphoSys Publishes Preclinical Data from MOR103 Program (Financial.de)
Antibody Shows Ability to Inhibit Disease in an Established RA Model MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
MORE INFO
|
11/13/2008
Examine the DNA Diagnostics: Technologies and Global Markets (Business Wire via Yahoo! Finance)
NEW YORK----Reportlinker.com announces that a new market research report related to the Medical devices industry is available in its catalogue.
MORE INFO
|
11/13/2008
MorphoSys Publishes Preclinical Data From MOR103 Program (GlobeNewswire via Yahoo! Finance)
MARTINSRIED, Germany, Nov. 13, 2008 -- MorphoSys AG announced today the publication of preclinical data from its most advanced proprietary drug development program MOR103, a fully human HuCAL antibody directed against GM-CSF.
MORE INFO
|
11/12/2008
Investigation Into Benign Moles And Malignant Melanoma (Medical News Today)
Research into a cancer that is on the rise in the UK is to be presented at the University of Leicester. It will discuss new studies at Leicester into the differences between benign and cancerous moles.
MORE INFO
|
11/12/2008
Benign or cancerous? (EurekAlert!)
( University of Leicester ) Findings from a new University of Leicester investigation into benign moles and malignant melanoma will be announced at a public lecture on Nov. 12.
MORE INFO
|